

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/jtd-23-1349">https://dx.doi.org/10.21037/jtd-23-1349</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The efficacy and pharmacological effects of pazopanib in animal and cell models will be shared, and details about the experiment can also be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	<i>In vitro</i> and <i>in vivo</i> experimental data such as experimental protocols, animal models and cell models will also be shared.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date.
7	To whom will you share the data?	Doctors and scientific researchers who are interested in the study of pulmonary fibrosis, TGF- $\beta$ and pazopanib.
8	For what type of analysis or purpose?	To analyze and evaluate the efficacy and pharmacological results of pazopanib in patients with pulmonary fibrosis.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: zqy15027605203@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.